CellBios Healthcare & Lifesciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CellBios Healthcare & Lifesciences is a private medical device and consumables company focused on enabling advanced therapies through its single-use bioprocess and cryopreservation systems. The company's core innovation lies in its specialized bag systems for freezing, thawing, transferring, and culturing biological materials, claiming to be the world's first and largest provider of specialized cryopreservation bags for CGT applications. With a broad portfolio spanning CGT therapy, bioprocessing, and medical infusion, CellBios operates as a B2B supplier to therapy developers, biobanks, and healthcare institutions. Its business model is based on manufacturing and selling disposable consumables and associated equipment, placing it in the 'Revenue Generating' stage as a supplier to the life sciences industry.

OncologyRegenerative MedicineGenetic Disorders

Technology Platform

Integrated platform for single-use bioprocessing and cryopreservation, specializing in polymer-based bag systems (EVA, PVC, Polyolefin, FEP) for fluid transfer, cell culture, and cryogenic storage of biological materials. Core innovation includes low-volume (500µL-30mL) multi-compartment cryopreservation bags and scalable freeze-thaw systems up to 25L.

Opportunities

The company is positioned to capitalize on the rapid expansion of the cell and gene therapy market, which creates sustained demand for specialized single-use consumables.

Its claimed first-mover advantage in low-volume cryopreservation bags addresses a critical need for storing high-value, small-batch therapies.

Further opportunity lies in expanding OEM partnerships and penetrating the large, established medical infusion disposables market for diversification.

Risk Factors

CellBios faces intense competition from large, established life science tools conglomerates with greater resources and global reach.

Its business is exposed to supply chain volatility for medical-grade polymers and is indirectly tied to the clinical and funding risks of the biotech sector.

Regulatory hurdles for medical device approvals in key markets also pose a significant execution risk.

Competitive Landscape

CellBios competes in the single-use bioprocessing market against giants like Sartorius, Danaher (Cytiva), and Thermo Fisher Scientific, as well as other specialists like Entegris and Meissner Filtration. Its niche focus on cryopreservation bags, particularly for CGT, differentiates it, but it must compete on innovation, customization, and cost against these deeply entrenched players with broader product ecosystems.

More companies in Cell & Gene Therapy →More companies in United States →